A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Weidmann, Eckhart; Heß, Georg; Chow, Kai Uwe; Krause, Stefan W.; Subklewe, Marion; Kruse, Judith; Weisel, Katja; Soekler, Martin; Kim, Soo-Zin; Napieralski, Simone; Rech, Jürgen; Dreyling, Martin; Jäger, Elke; Mitrou, Paris S.

doi:10.3109/10428190903580402

Cited by 33 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 55% of evaluable patients had PTCL-U, with an overall response rate of 61%, and a CR rate of 78% for previously untreated patients; however, regarding the survival a longer follow-up period is required. This study demonstrated that alemtuzumab can be combined with a chemotherapy regimen, nevertheless, haematological toxicity and cytomegalovirus reactivation remains the major limitations [96]. Others combination studies in PTCL in the same way as alemtuzumab with EPOCH or CHOP regimens are ongoing.…”

Section: Monoclonal Antibodies and Immunotoxinsmentioning

confidence: 87%

Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review

Rodríguez-Abreu

Filho

Zucca

2007

Hematological Oncology

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T-cells, and constitute less than 15% of all non-Hodgkin's lymphomas (NHLs) in adults. The current WHO classification recognizes nine distinct clinicopathologic peripheral T-cell NHLs, being the 'unspecified variant' (PTCL-U) the most common subtype. These neoplasms often present in advanced stage at diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. The rarity of these tumours requires additional studies to better understand their biology and search for new therapies which may hopefully improve the dismal outcome of most patients. This review aims to describe the pathobiological aspects as well the clinical characteristics and current therapeutic strategies of the PTCLs, with special attention to the group of PTCL-U

show abstract

Section: Monoclonal Antibodies and Immunotoxinsmentioning

confidence: 87%

Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review

Rodríguez-Abreu

Filho

Zucca

2007

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Overall, there were 6 treatment-related deaths in the trial, including 2 patients who developed an EBV-associated lymphoproliferative disorder due to profound immunosuppression related to the combination of fludarabine and alemtuzumab. 14 Currently, there are 2 ongoing phase 3 trials in Europe comparing dose-dense CHOP-14 with CHOP-14 plus subcutaneous alemtuzumab in younger patients (Ͻ 60 years, ACT-1) and older patients (Ͼ 60 years, ACT-2). Both trials include growth factor support, and ACT-1 also includes HDC/ASCT in responding patients.…”

Section: Chop With Alemtuzumabmentioning

confidence: 99%

Therapies for Peripheral T-Cell Lymphomas

Savage

2011

Hematology

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders that, for the most part, are associated with a very poor prognosis. The standard therapy for PTCLs is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines. With the exception of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK ϩ ALCL), the cure rate for PTCLs with CHOP is low, and limited evidence suggests that anthracyclines do not improve the prognosis. However, there is no compelling evidence that any other regimen or approach is superior. It remains challenging to compare alternative therapies or treatment strategies with CHOP because the majority of data are retrospective and include diverse patient populations. Recently, prospective studies have been initiated exclusively for PTCL, and in some, select histologic subtypes are evaluated in an effort to remove heterogeneity. Encouragingly, there have been several new therapies emerging with activity in PTCLs and exciting novel combinations under consideration that will hopefully move the field forward and improve outcome in this challenging group of diseases.

show abstract

“…Alternative approaches to CHOP have been fl udarabine-containing regimens alone or a combination with the monoclonal anti-CD52 antibody Alemtuzumab for PTCL/L, especially in T-PLL [35,50]. Alemtuzumab has also been successfully combined with CHOP protocols [34,38,43].…”

Section: Immuno-chemotherapy In Ptcl/lmentioning

confidence: 99%

Mature T-cell malignancies: a diagnostic and therapeutic challenge

Hopfinger

Herling

2009

memo

View full text Add to dashboard Cite

Peripheral T-/NK-cell lymphomas/leukaemias (PTCL/L) com prise a heterogeneous group of haematopoietic tumours, which originate from mature T-/NK-cells, and constitute less than 15% of all non-Hodgkin lymphomas (NHL) in adults of the Western hemisphere. Th ese neoplasms often present at advanced stage at the time of diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. In contrast to B-cell NHL, in which substantial clinical progress has been made with the introduction of monoclonal antibodies such as Rituximab, no comparable advances have been seen in PTCL/L. Moreover, no PTCL/L standard therapies have been established so far, and most PTCL/L have been treated in analogy to B-cell NHL. However, for PTCL/L these adapted protocols generally result in a much lower effi cacy along with frequent relapses. Approximately 30% of PTCL/L even show a primary refractory behaviour. In this review, the diagnostic features of the most common entities of PTCL/L and a proposed workup are presented. Moreover, currently applied therapeutic strategies like conventional chemotherapy or high-dose therapy as well as new drugs like histone deacetlyase inhibitors or immune modulatory reagents are discussed. We once more conclude that as no effi cient standard therapy has been established for most PTCL/L subtypes, treating pa tients with PTCL/L in clinical trials is strongly recommended.

show abstract

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Cited by 33 publications

References 23 publications

Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review

Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review

Therapies for Peripheral T-Cell Lymphomas

Mature T-cell malignancies: a diagnostic and therapeutic challenge

Contact Info

Product

Resources

About